...
机译:Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
Univ North Carolina Chapel Hill, Dept Med, Houpt Bldg,170 Manning Dr,CB 7305, Chapel Hill, NC 27599;
H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA;
Ohio State Univ, Dept Med, Comprehens Canc Ctr Arthur G James Canc Hosp, Columbus, OH USAWashington Univ, Dept Med, Sch Med, Siteman Canc Ctr, St Louis, MO USAUniv Southern Calif, Dept Med, Norris Comprehens Canc Ctr, Los Angeles, CA USAUniv Kentucky, Dept Med, Albert Chandler Med Ctr, Zion, IL USAUniv Wisconsin, Dept Med, Carbone Canc Ctr, Madison, WI USAUniv North Carolina Chapel Hill, Dept Dermatol, Chapel Hill, NC USAUniv North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC USALineberger Comprehens Canc Ctr, Immunogen Facil, Chapel Hill, NC USAUniv N Carolina, Translat Pathol Lab, Chapel Hill, NC USAUniv N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USADuke Canc Inst, Dept Med, Durham, NC USANCI, Canc Therapy Evaluat Program, Bethesda, MD USANatl Canc Inst NCI, UM1 Consortium, Expt Therapeut Clin Trials Network, Bethesda, MD USA;
CD19; IL-2 inducible kinase; ibrutinib; metastatic cutaneous melanoma; MAPK inhibitor refractory; PD-1 inhibitor refractory; PTEN; p16; tumor-infiltrating lymphocytes;